We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.30 | -1.01% | 29.45 | 29.42 | 29.45 | 29.73 | 29.20 | 29.71 | 5,982,230 | 18:57:36 |
By Dominic Chopping
STOCKHOLM--Shares in Swedish biotech company CombiGene AB more than doubled Tuesday after it said that it has entered into an exclusive collaboration and licensing agreement with Roche Holding AG subsidiary Spark Therapeutics for CG01, CombiGene's gene therapy developed for epilepsy.
Under the deal, Spark will have the exclusive worldwide license to develop, manufacture and commercialize CG01, with CombiGene receiving up to $328.5 million excluding royalties, with $8.5 million upon signing, as well as up to $50 million at several preclinical and clinical milestones.
CombiGene said its CG01 drug candidate is being developed to treat drug-resistant focal epilepsy, the most common form of epilepsy in adult epileptics.
"CombiGene's ambition is that CG01 will become the world's first curative treatment, compared to current treatments that only treat the symptoms."
The development of CG01 is in a late preclinical stage with the aim that clinical studies can be started next year. The company's production platform, developed together with its partners Cobra Biologics and Viralgen, is scalable up to full commercial production, it added.
CombiGene shares traded as high as SEK14.10 on Tuesday, from the morning's opening price of SEK6.29.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
October 12, 2021 07:08 ET (11:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions